Sebastian Duda / Shutterstock.com
TWi Pharmaceuticals has released a generic version of the Megace ES (megestrol acetate) drug, which is used to treat certain symptoms experienced by AIDS patients, just one day after a court ruled that it did not infringe a patent owned by Par Pharmaceutical.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
TWi Pharmaceuticals; Par Pharmaceutical; AIDS; Megace ES; ANDA; US District Court for the District of Maryland; generics
